Lower carotid intima media thickness is predicted by higher serum bilirubin in both non-diabetic and Type 2 diabetic subjects

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 161-165

  Dullaart, Robin P F ^a   Kappelle, Paul J W H ^a   de Vries, Rindert ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bilirubin; Intima media thickness; Transaminases; Type 2 diabetes mellitus

Indexed keywords

AMINOTRANSFERASE; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BILIRUBIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; GLUCOSE; METFORMIN; SULFONYLUREA; LIPID;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTERIAL WALL THICKNESS; ARTICLE; BILIRUBIN BLOOD LEVEL; CAROTID ARTERY; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; NON DIABETIC PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; SEX; BLOOD; PREDICTIVE VALUE;

BILIRUBIN; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TRANSAMINASES;

EID: 84866480062     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.08.029     Document Type: Article

References (38)

1. Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N., Ames, B.N., Bilirubin is an antioxidant of possible physiological importance. Science 235 (1987), 1043–1046.
2. Neuzil, J., Stocker, R., Free and albumin-bound bilirubin are efficient co-antioxidantsfor alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 269 (1994), 16712–16719.
3. Mayer, M., Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 46 (2000), 1723–1727.
4. Schwertner, H.A., Jackson, W.G., Tolan, G., Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 40 (1994), 18–23.
5. Breimer, L.H., Wannamethee, G., Ebrahim, S., Shaper, A.G., Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 41 (1995), 1504–1508.
6. Novotný L., Vítek, L., Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med 228 (2003), 568–571.
7. Ajja, R., Lee, D.C., Sui, X., Church, T.S., Steven, N.B., Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men. Am J Cardiol 108 (2011), 1438–1442.
8. O'Leary, D.H., Polak, J.F., Kronmal, R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 (1999), 14–22.
9. Lorenz, M.W., Markus, H.S., Bots, M.L., Rosvall, M., Sitzer, M., Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007), 459–467.
10. Erdogan, D., Gullu, H., Yildirim, E., et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184 (2006), 431–437.
11. Vítek, L., Novotný L., Sperl, M., Holaj, R., Spácil, J., The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 21 (2006), 408–414.
12. Stehouwer, C.D., Lambert, J., Donker, A.J., van Hinsbergh, V.W., Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34 (1997), 55–68.
13. Ceriello, A., Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Curr Opin Lipidol 17 (2006), 510–518.
14. Vítek, L., The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol 3 (2012), 1–7.
15. Yeh, S.Y., Doupis, J., Rahangdale, S., et al. Total serum bilirubin does not affect vascular reactivity in patients with diabetes. Vasc Med 14 (2009), 129–136.
16. Fukui, M., Tanaka, M., Yamazaki, M., Hasegawa, G., et al. Low serum bilirubin concentration in haemodialysis patients with Type 2 diabetes. Diabet Med 28 (2011), 96–99.
17. Simara, I., Moher, D., Hoey, J., Schultz, Altman, D.G., A catalogue of reporting guidelines for health research. Eur J Clin Invest 40 (2010), 35–53.
18. Grundy, S.M., Cleeman, J.I., Daniels, S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 112 (2005), 2735–2752.
19. Dutch College of General Practitioners, Standaard Diabetes mellitus Type 2. Huisarts Wet 3 (2006), 137–152.
20. Selzer, R.H., Hodis, H.N., Kwong-Fu, H., et al. Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 111 (1994), 1–11.
21. Kappelle, P.J., Gansevoort, R.T., Hillege, J.L., et al. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J Intern Med 269 (2011), 232–242.
22. Lu, M., Lyden, P.D., Brott, T.G., et al. Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. J Neurosci Methods 143 (2005), 209–216.
23. Heiss, G., Sharrett, A.R., Barnes, R., et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 134 (1991), 250–256.
24. Niskanen, L., Rauramaa, R., Miettinen, H., et al. Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 27 (1996), 1986–1992.
25. Dullaart, R.P.F., de Vries, R., van Tol, A., Sluiter, W.J., Lower plasma adiponectin is a marker of increased intima-media thickness associated with Type 2 diabetes mellitus and with male gender. Eur J Endocrinol 156 (2007), 387–394.
26. Saegeman, V.S., Vierendeels, I., Moens, M.J., Moerman, J., Should gender-related reference values be used for total bilirubin?. Clin Chem Lab Med 47 (2009), 1309–1310.
27. Clark, J.M., Brancati, F.L., Diehl, A.M., The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003), 960–967.
28. Dullaart, R.P.F., de Vries, R., Dallinga-Thie, G.M., Sluiter, W.J., van Tol, A., Phospholipid transfer protein activity is determined by Type 2 diabetes mellitus and metabolic syndrome, and is positively associated with serum transaminases. Clin Endocrinol (Oxf) 68 (2008), 375–381.
29. Ohnaka, K., Kono, S., Inoguchi, T., et al. Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of Type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract 88 (2010), 103–110.
30. Oda, E., Bilirubin is negatively associated with A1C independently of fasting plasma glucose, age, obesity, inflammation, hemoglobin, and iron in apparently healthy Japanese men and women. Diabetes Care, 33, 2010, e131.
31. Saely, C.H., Vonbank, A., Rein, P., et al. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. Clin Chim Acta 397 (2008), 82–86.
32. Petit, J.M., Guiu, B., Terriat, B., et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in Type 2 diabetic patients. J Clin Endocrinol Metab 94 (2009), 4103–4106.
33. Carallo, C., Mancuso, G., Mauro, G., et al. Hepatic steatosis, carotid atherosclerosis and metabolic syndrome: the STEATO Study. J Gastroenterol 44 (2009), 1156–1161.
34. Kim, S.K., Kim, D.J., Kim, S.H., et al. Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis. Diabetes Res Clin Pract 88 (2010), 111–116.
35. Schindhelm, R.K., Dekker, J.M., Nijpels, G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191 (2007), 391–396.
36. Peters, S.A., den Ruijter, H.M., Bots, M.L., Attenuation of rate of change in carotid intima-media thickness by lipid-modifying drugs: impact on clinical outcomes. Am J Cardiovasc Drugs 11 (2011), 253–263.
37. Risk Factors Collaboration, Emerging, Di Angelantonio, E., Sarwar, N., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009), 1993–2000.
38. Dekker, D., Dorresteijn, M.J., Pijnenburg, M., et al. The bilirubin-increasing drug atazanavir improves endothelial function in patients with Type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 31 (2011), 458–463.